Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial

BACKGROUND—: The Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX trial demonstrated superiority of cangrelor in reducing ischemic events at 48 hours in patients undergoing percutaneous coronary intervention compared with clopidogrel. METHODS...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Circ Cardiovasc Interv
Main Authors: Vaduganathan, Muthiah, Harrington, Robert A., Stone, Gregg W., Steg, Ph. Gabriel, Gibson, C. Michael, Hamm, Christian W., Price, Matthew J., Prats, Jayne, Deliargyris, Efthymios N., Mahaffey, Kenneth W., White, Harvey D., Bhatt, Deepak L.
Formato: Artigo
Idioma:Inglês
Publicado em: Lippincott Williams & Wilkins 2016
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4920208/
https://ncbi.nlm.nih.gov/pubmed/27313282
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/CIRCINTERVENTIONS.116.003612
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados